<DOC>
	<DOCNO>NCT01994252</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) heart failure ( HF ) two common heart condition encounter increase death suffering . When two condition occur patient , patient 's prognosis poor reduce quality life . These patient frequently admit hospital increase risk death . In HF patient AF time , would otherwise suitable candidate implantable defibrillator prevent sudden cardiac death , whether add pace ventricle reduce death suffering . Other study show add pace ventricle benefit HF patient mild moderate symptom regular heart rhythm . The Investigators want explore therapy benefit patient permanent irregular heart rhythm ( AF ) . The Investigators also assess cost effectiveness treatment strategy life quality patient . This study may dramatic impact way Investigators manage patient atrial fibrillation heart failure may improve outlook well patient .</brief_summary>
	<brief_title>Resynchronization/Defibrillation Ambulatory Heart Failure Trial Patients With Permanent Atrial Fibrillation</brief_title>
	<detailed_description>Heart failure ( HF ) increase prevalence incidence , common reason hospital admission patient age 65 . Therapy HF evolve last two decade . Cardiac resynchronization therapy ( CRT ) therapy attempt resynchronize sequence ventricular contraction heart failure ( HF ) patient leave ventricular ( LV ) systolic dysfunction ventricular dyssynchrony . CRT achieve stimulate RV LV together , synchronize right atrial excitation achieve atrio-ventricular synchrony . Clinical trial demonstrate CRT improve survival reduce HF hospitalization mild advance HF patient . In addition , CRT reverse remodel process associate reduction LV size , increase LV ejection fraction ( EF ) . This knowledge translate change practice guideline adoption CRT clinical practice benefit many HF patient CRT important state-of-the-art therapy HF patient LV systolic dysfunction , low LVEF , prolong QRS duration sinus rhythm , since vast majority CRT clinical research perform patient sinus rhythm . However , ~25 % HF patient permanent atrial fibrillation ( AF ) , effectiveness CRT clear . It therefore timely address question whether addition CRT optimal HF treatment , rate control ICD beneficial reduce all-cause mortality HF hospitalization HF patient permanent AF LV systolic dysfunction prolong QRS duration Objectives : determine whether cardiac resynchronization therapy reduce all-cause mortality hospitalization heart failure patient permanent atrial fibrillation , mild moderate heart failure , leave ventricular systolic dysfunction , prolong QRS duration , compare implantable cardioverter defibrillator ( ICD ) therapy alone Methods : This multi-centre randomized control trial two treatment group . The patient , primary physician heart failure caregiver blind treatment allocation . The device follow-up caregiver blind . Patients NYHA Class II III HF symptom , LVEF HF ≤ 35 % , permanent AF , optimal medical therapy QRS duration ≥ 130 m QRS morphology LBBB , QRS duration ≥ 150 m QRS morphology non-LBBB , Paced QRS include trial . Patients suitable candidate either 2 treatment strategy . There 950 patient randomize 1:1 ratio two group : 1 ) ICD-CRT , 2 ) ICD . All patient undergo baseline clinical evaluation , quality life assessment , medication assessment , blood chemistry include liver , renal , thyroid , NT-proBNP . The patient follow 1 month , 3 month , 6 month every 6 month . A history physical examination perform baseline follow-up visit . Blood work , quality life assessment , 6-minute walk distance also perform baseline follow-up visit . The Investigators anticipate study major impact HF patient permanent AF LV systolic dysfunction prolong QRS duration treat future .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>Patients NYHA Class II III HF symptom ( assessment last 3 month ) Permanent AF Optimal Medical Therapy HF least 3 month ( accord 2009 ACCF/AHA ESC 2012 recommendation , ) LVEF ≤ 35 % ( assessment last 6 month ) Candidacy ICD primary secondary prevention sudden cardiac death QRS duration ≥ 130 m QRS morphology LBBB , QRS duration ≥ 150 m QRS morphology nonLBBB Paced QRS Inhospital patient acute cardiac noncardiac illness require intensive care Intravenous inotropic agent last 4 day Patients life expectancy le one year noncardiac cause . Expected undergo cardiac transplantation within one year ( status I ) Acute coronary syndrome ( include MI ) &lt; 4 week Unable unwilling provide inform consent Uncorrected uncorrectable primary valvular disease Restrictive , hypertrophic reversible form cardiomyopathy Severe primary pulmonary disease cor pulmonale Tricuspid prosthetic valve Patients include clinical trial affect objective study Coronary revascularization ( CABG PCI ) &lt; 3 month Patients exist ICD CRT pacemaker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>defibrillator</keyword>
	<keyword>cardiac resynchronization</keyword>
</DOC>